IQVIA Holdings, Inc.
IQV
$258.11
-0.72%
IQVIA Holdings Inc. is a global leader in clinical research and technology solutions for the life sciences industry, formed in 2016 through the merger of Quintiles and IMS Health. The company operates two primary segments: Research & Development Solutions, which provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, and regulatory approval, and Commercial Solutions, which helps clients optimize product commercialization through analytics, technology, and outsourced sales services. IQVIA's distinct competitive identity rests on its unrivaled proprietary healthcare data assets and analytics platform, which create high switching costs and a moat that pure-play CROs cannot easily replicate. The current investor narrative centers on accelerating revenue growth — Q2 2026 revenue rose 8.7% year-over-year to $4.37 billion — alongside a dramatic stock re-rating that saw shares surge roughly 49% over the past six months, driven by optimism around AI-enabled clinical trial efficiency, expanding margins, and a strong buy consensus from 19 covering analysts.…
IQV
IQVIA Holdings, Inc.
$258.11
Related headlines
Investment Opinion: Should I buy IQV Today?
IQVIA is rated a Hold with a bullish bias, reflecting a balance between its strong competitive moat and revenue re-acceleration against margin compression and a leveraged balance sheet. The analyst consensus is a strong buy (mean rating 1.41) with an average target price of $288.74, implying 11.8% upside from the current price of $258.21. The core thesis is that IQVIA's unrivaled healthcare data assets and analytics platform create high switching costs and a durable moat, but the stock's 49% six-month rally has already priced in much of the near-term optimism.
The supporting evidence for a Hold is mixed but leans positive. Revenue grew 8.74% YoY in Q2 2026 to $4.368 billion, with a forward consensus estimate of $22.25 billion, indicating continued mid-to-high single-digit growth. Free cash flow is robust at $2.613 billion TTM, funding $398 million in buybacks and $221 million in debt repayment in Q2 alone. However, profitability is under pressure: net margin fell to 5.86% from 6.62%, and operating margin declined to 11.58% from 12.60%. The forward PE of 17.8x implies 60% EPS growth, which is optimistic given the margin headwinds. The PEG ratio of 6.34 and PB of 5.96x suggest the stock is not cheap relative to its growth prospects.
The biggest risks that could invalidate the thesis are continued margin compression, a breakdown in revenue growth below 5%, and a leveraged balance sheet that limits financial flexibility. This Hold would upgrade to Buy if net margin stabilizes above 6% and revenue growth accelerates above 10%, or if the stock pulls back to the $220-$230 range, improving the risk/reward. It would downgrade to Sell if net margin falls below 5% or if revenue growth decelerates below 5% for two consecutive quarters. Relative to its own history, the trailing PE of 28.5x is in the middle-to-upper portion of its 18.7x-39.4x range, suggesting the stock is fairly valued to slightly overvalued. Relative to peers, the PS ratio of 2.38x appears moderate, but the PEG ratio of 6.34 is a red flag. Overall, IQVIA is fairly valued, with limited margin of safety at current levels.
Sign up to view all
IQV 12-Month Price Forecast
IQVIA presents a balanced risk/reward profile at current levels, with the bull case supported by revenue re-acceleration and a strong analyst consensus, but tempered by margin compression and a leveraged balance sheet. The stock's 49% six-month rally has already priced in much of the near-term optimism, and the forward PE of 17.8x implies 60% EPS growth that may be challenging to achieve if margins continue to decline. The recent momentum deceleration, with a -2.7% relative strength over the past month, suggests the stock is digesting its gains and could be vulnerable to a pullback. I would upgrade to bullish if net margin stabilizes above 6% and revenue growth accelerates above 10%, or downgrade to bearish if net margin falls below 5% or revenue growth decelerates below 5%. The key monitorable is the Q3 2026 earnings report, particularly the trajectory of SG&A and interest expenses.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on IQVIA Holdings, Inc.'s 12-month outlook, with a consensus price target around $290.84 and implied upside of +12.7% versus the current price.
Average Target
$290.84
0 analysts
Implied Upside
+12.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$250 - $345
Analyst target range
IQVIA is covered by 19 analysts with a strong buy consensus recommendation (mean rating of 1.41 on a 1-5 scale where 1 is Strong Buy), and the average price target of $288.74 implies approximately 11.8% upside from the current price of $258.21. The distribution of ratings is overwhelmingly bullish, with recent actions from RBC Capital (Outperform), Truist Securities (Buy), JP Morgan (Overweight), Baird (Outperform), BMO Capital (Outperform), Stifel (Buy), TD Cowen (Buy), and Mizuho (Outperform) all reaffirming positive views, while Morgan Stanley maintains an Equal Weight stance as the notable holdout. The consensus leans clearly bullish, supported by the strong buy rating and the fact that the average target sits above the current price, though the modest 11.8% implied upside suggests analysts see the stock as fairly valued after its substantial run. The target range spans from a low of $250 to a high of $345, a spread of $95 or roughly 38% of the low target, indicating meaningful disagreement about the company's trajectory. The high target of $345 would require approximately 33.6% upside and likely assumes accelerating revenue growth, margin expansion from operating leverage, successful AI-driven clinical trial efficiency gains, and multiple expansion as the market rewards IQVIA's data moat. The low target of $250, just 3.2% below the current price, prices in a more conservative scenario of stable but unspectacular growth, potential margin compression from rising costs, and competitive pressures in the CRO space. The wide target spread signals elevated uncertainty, and the fact that the stock is trading near the low end of the analyst range suggests the market may be pricing in a more cautious outlook than the consensus implies.
Bulls vs Bears: IQV Investment Factors
The bull case currently has stronger evidence, anchored by revenue re-acceleration to 8.74% YoY, a strong buy consensus from 19 analysts, and robust free cash flow of $2.61 billion. However, the bear case is gaining traction due to margin compression (net margin down to 5.86% from 6.62%), a leveraged balance sheet with a current ratio of 0.749, and recent momentum deceleration with a -2.7% relative strength over the past month. The single most important tension is whether IQVIA can translate its revenue growth into margin expansion and EPS growth to justify the forward PE of 17.8x, which implies 60% earnings growth. If margins continue to compress, the stock's premium valuation and 49% six-month rally could be vulnerable to a sharp correction toward the $210-$220 support zone.
Bullish
- Revenue re-acceleration to 8.7% YoY: Q2 2026 revenue rose 8.74% year-over-year to $4.368 billion, up from $4.017 billion in Q2 2025, continuing a sequential climb from $3.829 billion in Q1 2025. This steady mid-to-high single-digit growth, supported by a $22.25 billion forward consensus revenue estimate, demonstrates that IQVIA's data and analytics moat is converting into durable top-line expansion.
- Strong buy consensus with 11.8% upside: All 19 covering analysts rate IQVIA a strong buy (mean rating 1.41), with an average price target of $288.74 implying 11.8% upside from $258.21. The high target of $345 suggests 33.6% upside if AI-driven trial efficiency and margin expansion materialize.
- Robust free cash flow of $2.61B TTM: IQVIA generated $2.613 billion in trailing twelve-month free cash flow, with Q2 2026 alone contributing $360 million ($558 million operating cash flow less $198 million capex). This internal funding capacity supports continued share repurchases ($398 million in Q2) and debt reduction ($221 million in Q2).
- Forward PE of 17.8x implies 60% EPS growth: The forward PE of 17.8x against consensus EPS of $20.67 represents a 37% compression from the trailing PE of 28.5x, implying the market expects roughly 60% earnings growth. If IQVIA delivers on this, the stock is reasonably valued for a company with a 20.9% ROE and a wide competitive moat.
Bearish
- Margin compression despite revenue growth: Q2 2026 net margin fell to 5.86% from 6.62% a year earlier, while operating margin declined to 11.58% from 12.60%. Rising SG&A costs of $574 million and interest expense of $197 million are consuming a growing share of pre-tax income, with operating income flat at $506 million despite 8.7% revenue growth.
- Leveraged balance sheet with weak liquidity: The debt-to-equity ratio of 2.49 and current ratio of 0.749 reveal a highly leveraged balance sheet with limited short-term liquidity cushion. Interest coverage of just 2.57x and a cash flow-to-debt ratio of 0.034 mean debt servicing consumes a significant portion of operating cash flow, constraining financial flexibility.
- Momentum deceleration and relative weakness: The stock is down 2.1% over the past month versus a 0.6% gain for SPY, producing a relative strength of -2.7% — a sharp divergence from the 3-month relative strength of +21.4%. This deceleration suggests the summer rally is being digested and raises the risk of profit-taking near the 52-week high of $277.40.
- Elevated PEG ratio of 6.34 signals overvaluation: The PEG ratio of 6.34 is well above the typical 1.0-2.0 range for fairly valued growth stocks, suggesting the market is pricing in significant future growth that may already be reflected in the multiple. The PB ratio of 5.96x is also elevated, reflecting substantial intangible assets from the 2016 merger.
IQV Technical Analysis
IQVIA is in a powerful sustained uptrend, with the stock up 26.4% over the past year and an extraordinary 49.0% over six months, massively outperforming the S&P 500's 15.0% and 17.4% respective gains. At $258.21, the stock trades at approximately 84% of its 52-week range (52-week low of $154.50, high of $277.40), positioning it in the upper quartile of its annual band — a zone that signals strong momentum but also raises the risk of profit-taking near prior highs. The 52-week range spans $122.90, and the stock's current position near the top reflects a market that has aggressively repriced IQVIA higher following its July 2026 earnings-driven breakout. Recent momentum has cooled, however, with the stock down 2.1% over the past month versus a 0.6% gain for SPY, producing a relative strength of -2.7% — a notable divergence from the 3-month relative strength of +21.4% and 6-month relative strength of +31.7%. This deceleration suggests the stock is digesting its massive summer rally rather than reversing trend, though the 1-month pullback of 2.1% against a 3-month gain of 24.7% warrants monitoring for signs of momentum exhaustion. The stock's beta of 1.186 indicates roughly 19% more volatility than the broader market, meaning position sizing should account for amplified drawdowns during risk-off episodes. Key technical support sits at the 52-week low of $154.50, with intermediate support likely around the $240-$250 zone where the stock consolidated in August; resistance is defined by the 52-week high of $277.40, and a decisive breakout above that level would confirm the next leg of the uptrend, while a breakdown below $240 would signal a deeper mean-reversion toward the $210-$220 area. The maximum drawdown of -35.87% over the trailing period underscores that despite the strong trend, this stock is capable of sharp corrections.
Beta
1.17
1.17x market volatility
Max Drawdown
-35.9%
Largest decline past year
52-Week Range
$155-$277
Price range past year
Annual Return
+28.5%
Cumulative gain past year
| Period | IQV Return | S&P 500 |
|---|---|---|
| 1m | -3.6% | +0.9% |
| 3m | +23.5% | +3.4% |
| 6m | +54.2% | +14.4% |
| 1y | +28.5% | +16.2% |
| ytd | +14.5% | +14.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IQV Fundamental Analysis
IQVIA's revenue trajectory is clearly re-accelerating, with Q2 2026 revenue of $4.368 billion representing 8.74% year-over-year growth versus $4.017 billion in Q2 2025. The multi-quarter trend shows consistent sequential improvement: revenue climbed from $3.829 billion in Q1 2025 to $4.151 billion in Q1 2026, and from $4.017 billion in Q2 2025 to $4.368 billion in Q2 2026, with the Research & Development Solutions segment contributing $2.575 billion and Commercial Solutions adding $1.793 billion in the most recent quarter. This steady mid-to-high single-digit growth, combined with a $22.25 billion consensus revenue estimate for the forward year, implies the company is successfully converting its data and analytics moat into durable top-line expansion. Profitability remains solid but faces margin pressure: Q2 2026 net income was $256 million with a net margin of 5.86%, down from $266 million and 6.62% in Q2 2025, while gross margin held relatively steady at 32.85% versus 32.94% a year earlier. Operating income of $506 million in Q2 2026 was flat versus the prior year's $506 million, and the operating margin of 11.58% declined from 12.60%, reflecting rising SG&A costs of $574 million and interest expense of $197 million that consumed a meaningful portion of pre-tax income. The company's TTM free cash flow of $2.613 billion provides substantial internal funding capacity, though the debt-to-equity ratio of 2.49 and current ratio of 0.749 reveal a leveraged balance sheet with limited short-term liquidity cushion. ROE of 20.9% is healthy and reflects the company's heavy leverage, but the cash flow-to-debt ratio of just 0.034 and interest coverage of 2.57x highlight that debt servicing consumes a significant share of operating cash flow. Q2 2026 operating cash flow was $558 million with capital expenditures of $198 million, yielding $360 million in free cash flow, while the company continued returning capital via $398 million in stock repurchases and $221 million in debt repayment.
Quarterly Revenue
$4.4B
2026-06
Revenue YoY Growth
+8.7%
YoY Comparison
Gross Margin
32.9%
Latest Quarter
Free Cash Flow
$2.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IQV Overvalued?
Because IQVIA is profitable — Q2 2026 net income of $256 million and TTM EPS of $0.035 — the PE ratio is the appropriate primary valuation metric, and the trailing PE of 28.5x compares to a forward PE of 17.8x, a 37% compression that implies the market expects substantial earnings growth ahead. The forward PE of 17.8x against consensus estimated EPS of $20.67 suggests that if IQVIA delivers on expectations, the stock is reasonably valued for a company growing revenue at nearly 9% with a 20.9% ROE. Relative to the broader healthcare and diagnostics/research sector, IQVIA's trailing PE of 28.5x and PS ratio of 2.38x appear moderate, though the EV/EBITDA of 15.3x and PEG ratio of 6.34 suggest the market is pricing in significant future growth that may already be reflected in the multiple. The PB ratio of 5.96x is elevated, reflecting the company's asset-light model and substantial intangible assets from its merger history. Historically, IQVIA's PE ratio has ranged from roughly 18.7x (Q4 2025) to 39.4x (Q1 2024), placing the current 28.5x in the middle-to-upper portion of its own band — not stretched to prior peaks but well above the trough. The PS ratio of 2.38x is notably below the historical range of 6.7x to 12.1x seen in 2022-2024, though this comparison is distorted by the stock's price appreciation and revenue base changes; the current PS of 2.38x versus the Q2 2026 historical reading of 7.40x reflects data normalization differences rather than a true valuation shift. The forward PE of 17.8x versus the trailing 28.5x implies the market is pricing in roughly 60% EPS growth, which is an optimistic but not implausible expectation given the company's operating leverage potential.
PE
28.5x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 19x~44x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
18.0x
Enterprise Value Multiple
Investment Risk Disclosure
IQVIA's financial and operational risks are significant, primarily stemming from its leveraged balance sheet and margin pressure. The debt-to-equity ratio of 2.49 and current ratio of 0.749 indicate limited short-term liquidity, while interest coverage of just 2.57x and a cash flow-to-debt ratio of 0.034 mean debt servicing consumes a substantial portion of operating cash flow. Despite 8.74% revenue growth in Q2 2026, net margin fell to 5.86% from 6.62% a year earlier, and operating margin declined to 11.58% from 12.60%, as SG&A costs rose to $574 million and interest expense reached $197 million. This margin compression, if sustained, could undermine the company's ability to deleverage and fund growth initiatives.
Market and competitive risks are elevated given IQVIA's premium valuation and high beta. The stock trades at a trailing PE of 28.5x and a PEG ratio of 6.34, well above typical fair-value ranges, leaving it vulnerable to multiple compression if growth disappoints. With a beta of 1.186, IQV is roughly 19% more volatile than the broader market, amplifying drawdowns during risk-off episodes. Competitive pressures in the CRO space, particularly from pure-play CROs and technology-enabled entrants, could erode IQVIA's data moat and pricing power. Additionally, the recent momentum deceleration—down 2.1% over the past month versus a 0.6% gain for SPY—suggests the stock may be digesting its summer rally, and a breakdown below $240 could trigger a deeper mean-reversion toward the $210-$220 area.
The worst-case scenario for IQVIA would involve a combination of margin compression, revenue deceleration, and multiple contraction. If net margin continues to decline and revenue growth slows below 5%, the forward PE of 17.8x could compress toward the historical trough of 18.7x, implying a stock price near $210. A more severe scenario, such as a loss of a major client or a failed AI initiative, could push the stock toward its 52-week low of $154.50, representing a 40% decline from the current price of $258.21. The maximum drawdown of -35.87% over the trailing period underscores that IQV is capable of sharp corrections, and investors could lose 35-40% in an adverse scenario.
FAQ
The key risks of holding IQV are ranked by severity: First, margin compression is the most immediate threat, with net margin falling to 5.86% from 6.62% and operating margin declining to 11.58% from 12.60%, as SG&A costs and interest expense consume a growing share of revenue. Second, the leveraged balance sheet poses a financial risk, with a debt-to-equity ratio of 2.49, a current ratio of 0.749, and interest coverage of just 2.57x, limiting financial flexibility. Third, competitive pressures in the CRO space could erode IQVIA's data moat and pricing power, particularly from technology-enabled entrants. Fourth, macro sensitivity is a concern given the beta of 1.186, meaning the stock is 19% more volatile than the market and could suffer amplified drawdowns during risk-off episodes. Finally, the stock's premium valuation (PEG 6.34) leaves it vulnerable to multiple compression if growth disappoints.
The 12-month forecast for IQV is based on three scenarios: Bull case (25% probability) targets $300-$345, assuming AI-driven efficiency gains, margin expansion, and double-digit revenue growth. Base case (55% probability) targets $270-$300, assuming mid-to-high single-digit revenue growth and gradual margin improvement, in line with the analyst average target of $288.74. Bear case (20% probability) targets $210-$250, assuming continued margin compression, revenue deceleration below 5%, and multiple contraction. The most likely scenario is the base case, with the key assumption being that net margin stabilizes around 6.0-6.5% and revenue growth remains in the 7-9% range. The wide analyst target range of $250 to $345 reflects significant uncertainty, and the stock's recent momentum deceleration suggests a period of consolidation before the next leg higher.
IQV appears fairly valued to slightly overvalued at current levels. The trailing PE of 28.5x is in the middle-to-upper portion of its historical range of 18.7x to 39.4x, while the forward PE of 17.8x implies 60% EPS growth, which is optimistic given margin headwinds. The PEG ratio of 6.34 is well above the typical fair-value range of 1.0-2.0, suggesting the market is pricing in significant future growth. The PS ratio of 2.38x is moderate compared to peers, but the PB ratio of 5.96x is elevated due to substantial intangible assets. Overall, the market is paying a premium for IQVIA's data moat and growth prospects, but the valuation leaves little room for error if margins continue to compress.
IQV is a good buy for long-term investors seeking exposure to the life sciences industry with a wide-moat business, but the current risk/reward is balanced. The stock trades at $258.21, with an average analyst target of $288.74 implying 11.8% upside, and a strong buy consensus from 19 analysts. However, the trailing PE of 28.5x and PEG ratio of 6.34 suggest the stock is fully valued, and the net margin has compressed to 5.86% from 6.62% a year ago. The biggest downside risk is a breakdown below the $240 support level, which could trigger a decline toward the 52-week low of $154.50, representing a 40% loss. For investors with a long-term horizon and tolerance for volatility (beta 1.186), IQV is a solid core holding, but waiting for a pullback to the $220-$230 range would improve the risk/reward.
IQV is best suited for long-term investment, with a suggested minimum holding period of 2-3 years. The company's wide economic moat, driven by its proprietary healthcare data assets and analytics platform, supports durable long-term growth, and its revenue is re-accelerating at 8.74% YoY. However, the stock's high beta of 1.186 and maximum drawdown of -35.87% make it unsuitable for short-term trading, as it is prone to sharp corrections. The lack of a dividend (payout ratio 0%) means returns are entirely dependent on capital appreciation, which requires patience. For short-term traders, the stock's recent momentum deceleration and relative weakness (-2.7% over the past month) suggest a cautious approach, with key support at $240 and resistance at $277.40. Long-term investors should focus on the company's ability to expand margins and deleverage its balance sheet over the next 2-3 years.